2018 대한부정맥학회 NOAC 사용 지침: 특별한 상황에서의 약물 복용(관상동맥질환, 용량 혼동시, 심율동 전환, 뇌졸중 발생, 악성종양) 및 기타

키워드

참고문헌 (195)

1. Gwyn JCV, "Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention : a viewpoint", Eur Heart J Cardiovasc Pharmacother, 3, pp.157~162 (2017)
2. Lopes RD, "Atrial fibrillation and acute myocardial infarction : antithrombotic therapy and outcomes", Am J Med, 125, pp.897~905 (2012)
3. Dans AL, "Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy(RE-LY)trial", Circulation, 127, pp.634~640 (2013)
4. Mega JL, "Rivaroxaban in patients with a recent acute coronary syndrome", N Engl J Med, 366, pp.9~19 (2012)
5. Alexander JH, "Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation:insights from the ARISTOTLE trial", Eur Heart J, 35, pp.224~232 (2014)
6. Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)
7. Rubboli A, "Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding : insights from the warfarin and coronary stenting(War-Stent)registry", Cardiovasc Revasc Med, 18, pp.425~430 (2017)
8. Sra S, "Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation : Insights from the Canadian observational AntiPlatelet sTudy", Am Heart J, 180, pp.82~89 (2016)
9. Lopes RD, "Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease", Am J Med, 129, pp.592~599. e591 (2016)
10. ACTIVE Writing Group of the ACTIVE Investigators, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events(ACTIVE W) : a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)
11. Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
12. Ibanez B, "2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 39, pp.119~177 (2018)
13. Valgimigli M, "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)", Eur Heart J, 39, pp.213~260 (2018)
14. Piccini JP, "Triple therapy for atrial fibrillation after PCI", N Engl J Med, 377, pp.1580~1582 (2017)
15. Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention(PCI)with stent placement : Rationale and design of the ENTRUST-AF PCI trial", Am Heart J, 196, pp.105~112 (2018)
16. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
17. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)
18. Ferguson JJ, "Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy : primary results of the SYNERGY randomized trial", JAMA, 292, pp.45~54 (2004)
19. Valgimigli M, "Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management : a randomised multicentre trial", Lancet, 385, pp.2465~2476 (2015)
20. Lip GY, "Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and", or undergoing percutaneous coronary or valve interventions : a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association(EHRA), European Association of Percutaneous Cardiovascular Interventions(EAPCI)and European Association of Acute Cardiac Care(ACCA)endorsed by the Heart Rhythm Society(HRS)and Asia-Pacific Heart Rhythm Society(APHRS), 2014, pp.35, 3155~3179
21. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)
22. Povsic TJ, "A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome : the design of the GEMINI-ACS-1 phase II study", Am Heart J, 174, pp.120~128 (2016)
23. Lamberts M, "Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention : a nationwide cohort study", Circulation, 126, pp.1185~1193 (2012)
24. Windecker S, "Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease : an accompanying article of the task force of the 2018 ESC", EACTS guidelines on myocardial revascularization, 2019, pp.40, 204~212
25. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
26. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
27. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
28. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
29. January CT, "2014 AHA", ACC, American Heart Association task force on practice guidelines and the Heart Rhythm Society, pp.Circulation, 2014[DOI]
30. Cappato R, "Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation", Eur Heart J, 35, pp.3346~3355 (2014)
31. Goette A, "Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation(ENSURE-AF) : a randomised, open-label, phase 3b trial", Lancet, 388, pp.1995~2003 (2016)
32. Ezekowitz MD, "Apixaban compared to heparin", vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion : the EMANATE trial, 2018, pp.39, 2959~2971
33. McCready JW, "Incidence of left atrial thrombus prior to atrial fibrillation ablation : is pre-procedural transoesophageal echocardiography mandatory", Europace, 12, pp.927~932 (2010)
34. Puwanant S, "Role of the CHADS2Score in the evaluation of thromboembolic risk in patients with atrial fibrillation undergoing transesophageal echocardiography before pulmonary vein isolation", J Am Coll Cardiol, 54, pp.2032~2039 (2009)
35. Scherr D, "Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation", J Cardiovasc Electrophysiol, 20, pp.379~384 (2009)
36. Hansen ML, "Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy", Europace, 17, pp.18~23 (2014)
37. Grönberg T, "Anticoagulation, CHA2DS2VASc Score, and thromboembolic risk of cardioversion of acute atrial fibrillation(from the FinCV Study)", J Am Coll Cardiol, 117, pp.1294~1298 (2016)
38. Nuotio I, "Time to cardioversion for acute atrial fibrillation and thromboembolic complications", JAMA, 312, pp.647~649 (2014)
39. Flaker G, "Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation : insights from the ARISTOTLE trial(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation)", J Am Coll Cardiol, 63, pp.1082~1087 (2014)
40. Piccini JP, "Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial", J Am Coll Cardiol, 61, pp.1998~2006 (2013)
41. Lip GY, "Left atrial thrombus resolution in atrial fibrillation or flutter : results of a prospective study with rivaroxaban(X-TRA)and a retrospective observational registry providing baseline data(CLOT-AF)", Am Heart J, 178, pp.126~134 (2016)
42. Purrucker JC, "Coagulation testing in acute ischemic stroke patients taking non–vitamin K antagonist oral anticoagulants", Stroke, 48, pp.152~158 (2017)
43. Powers WJ, "2018 guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2018, pp.49, e46~e110
44. Tse D, "Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab", J Neurol Neurosurg Psychiatry, 89, pp.549~550 (2018)
45. Kermer P, "Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-a national case collection", Int J Stroke, 12, pp.383~391 (2017)
46. David J. Seiffge, "Intravenous Thrombolysis in Patients with Stroke Taking Rivaroxaban Using Drug Specific Plasma Levels: Experience with a Standard Operation Procedure in Clinical Practice", 대한뇌졸중영문학회지, 19(3), pp.347~355 (2017), 대한뇌졸중학회
47. Williams DO, "Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction : a report from the NHLBI thrombolysis in myocardial infarction trial", Circulation, 73, pp.338~346 (1986)
48. Ebner M, "Emergency coagulation assessment during treatment with direct oral anticoagulants : limitations and solutions", Stroke, 48, pp.2457~2463 (2017)
49. Ebner M, "Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants", Crit Care, 21, pp.32~ (2017)
50. Drouet L, "Measuring non-vitamin K antagonist oral anticoagulant levels : when is it appropriate and which methods should be used", Int J Stroke, 11, pp.748~758 (2016)
51. Saver J, "Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke : a meta-analysis", JAMA, 316, pp.1279~1288 (2016)
52. Nogueira RG, "Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct", N Engl J Med, 378, pp.11~21 (2018)
53. Albers GW, "Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging", N Engl J Med, 378, pp.708~718 (2018)
54. Wahlgren N, "Mechanical thrombectomy in acute ischemic stroke : consensus statement by ESO-Karolinska Stroke Update 2014", 2015, supported by ESO, ESMINT, ESNR and EAN, 2016, pp.11, 134~147
55. Purrucker JC, "Safety of endovascular thrombectomy in patients receiving non-vitamin K antagonist oral anticoagulants", Stroke, 47, pp.1127~1130 (2016)
56. Hankey GJ, "Intracranial hemorrhage and novel anticoagulants for atrial fibrillation : what have we learned", Curr Cardiol Rep, 16, pp.480~ (2014)
57. Lopes RD, "Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy", Blood, 129, pp.2980~2987 (2017)
58. Lopes RD, "Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy", Blood, 129, pp.2980~2987 (2017)
59. Inohara T, "Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality", JAMA, 319, pp.463~473 (2018)
60. Hemphill JC 3rd, "Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2015, pp.46, 2032~2060
61. Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)
62. Gerner ST, "Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage", Ann Neurol, 83, pp.186~196 (2018)
63. Diener HC, "Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation : part 2", Eur Heart J, 38, pp.860~868 (2016)
64. Nielsen PB, "Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation : propensity weighted nationwide cohort study", BMJ, 356, pp.j510~ (2017)
65. Yao X, "Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction", J Am Coll Cardiol, 69, pp.2779~2790 (2017)
66. Paciaroni M, "Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants(RAF-NOACs)study", J Am Heart Assoc, 6, pp.e007034~ (2017)
67. Ahmed N, "Recommendations from the ESO-karolinska stroke update conference, Stockholm 13-15 November 2016", Eur Stroke J, 2, pp.95~102 (2017)
68. Paciaroni M, "Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation : effect of anticoagulation and its timing : the RAF study", Stroke, 46, pp.2175~2182 (2015)
69. Paciaroni M, "Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke : a meta-analysis of randomized controlled trials", Stroke, 38, pp.423~430 (2007)
70. Orrapin S, "Carotid endarterectomy for symptomatic carotid stenosis", Cochrane Database Syst Rev, 6, pp.CD001081~ (2017)
71. Brønnum Nielsen P, "Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation : a nationwide cohort study", Chest, 147, pp.1651~1658 (2015)
72. Korompoki E, "Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation", Neurology, 89, pp.687~696 (2017)
73. Banerjee G, "The increasing impact of cerebral amyloid angiopathy : essential new insights for clinical practice", J Neurol Neurosurg Psychiatry, 88, pp.982~994 (2017)
74. Biffi A, "Oral anticoagulation and functional outcome after intracerebral hemorrhage", Ann Neurol, 82, pp.755~765 (2017)
75. Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
76. Rietbrock S, "Chronic atrial fibrillation : incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack(CHADS2)risk stratification scheme", Am Heart J, 156, pp.57~64 (2008)
77. Wolff A, "Impact of advanced age on management and prognosis in atrial fibrillation : insights from a population-based study in general practice", Age Ageing, 44, pp.874~878 (2015)
78. Wolf PA, "Atrial fibrillation as an independent risk factor for stroke : the Framingham Study", Stroke, 22, pp.983~988 (1991)
79. Fohtung RB, "Effect of new oral anticoagulants on prescribing practices for atrial fibrillation in older adults", J Am Geriatr Soc, 65, pp.2405~2412 (2017)
80. Bai Y, "Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation : a systematic review and meta-regression analysis", Age Ageing, 47, pp.9~17 (2018)
81. Fumagalli S, "Frailty syndrome: an emerging clinical problem in the everyday management of clinical arrhythmias. The results of the European Heart Rhythm Association survey", Europace, 19, pp.1896~1902 (2017)
82. Wehling M, "Appropriateness of oral anticoagulants for the long-term treatment of atrial fibrillation in older people : results of an evidence-based review and international consensus validation process(OAC-FORTA 2016)", Drugs Aging, 34, pp.499~507 (2017)
83. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
84. Kato ET, "Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial", J Am Heart Assoc, 5, pp.e003432~ (2016)
85. Eikelboom JW, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation : an analysis of the randomized evaluation of long-term anticoagulant therapy(RE-LY)trial", Circulation, 123, pp.2363~2372 (2011)
86. Halperin JL, "Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation(ROCKET AF)", Circulation, 130, pp.138~146 (2014)
87. Halvorsen S, "Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation : observations from the ARISTOTLE trial", Eur Heart J, 35, pp.1864~1872 (2014)
88. Okumura K, "Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies : rationale and design of the ELDERCARE-AF study", Am Heart J, 194, pp.99~106 (2017)
89. Fried LP, "Frailty in older adults : evidence for a phenotype", J Gerontol A Biol Sci Med Sci, 56, pp.M146~M157 (2001)
90. Rockwood K, "A global clinical measure of fitness and frailty in elderly people", CMAJ, 173, pp.489~495 (2005)
91. Rockwood K, "A brief clinical instrument to classify frailty in elderly people", Lancet, 353, pp.205~206 (1999)
92. Rubenstein LZ., "Falls in older people: epidemiology, risk factors and strategies for prevention", Age Ageing, 35(Suppl 2), pp.ii37~ii41 (2006)
93. Hylek EM, "Translating the results of randomized trials into clinical practice : the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation", Stroke, 37, pp.1075~1080 (2006)
94. Man-Son-Hing M, "Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls", Arch Intern Med, 159, pp.677~685 (1999)
95. Steffel J, "Edoxaban versus warfarin in atrial fibrillation patients at risk of falling : ENGAGE AF–TIMI 48 analysis", J Am Coll Cardiol, 68, pp.1169~1178 (2016)
96. Rao MP, "Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation : insights from the ARISTOTLE trial", Am J Med, 131, pp.269~275. e262 (2018)
97. Martinez BK, "Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation", J Am Heart Assoc, 7, pp.e008643~ (2018)
98. Hanon O, "Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people", Arch Cardiovasc Dis, 106, pp.303~323 (2013)
99. Sherrington C, "Effective exercise for the prevention of falls : a systematic review and meta-analysis", J Am Geriatr Soc, 56, pp.2234~2243 (2008)
100. Tricco AC, "Comparisons of interventions for preventing falls in older adults : a systematic review and meta-analysis", JAMA, 318, pp.1687~1699 (2017)
101. Garcia-Ptacek S, "Prestroke mobility and dementia as predictors of stroke outcomes in patients over 65 years of age : a cohort study from the swedish dementia and stroke registries", J Am Med Dir Assoc, 19, pp.154~161 (2018)
102. Friberg L, "Less dementia with oral anticoagulation in atrial fibrillation", Eur Heart J, 39, pp.453~460 (2018)
103. Dietzel J, "Does atrial fibrillation cause cognitive decline and dementia?", Europace, 20, pp.408~419 (2018)
104. Desteghe L, "Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation", Eur Heart J, 39, pp.1394~1403 (2018)
105. "Obesity and overweight" (2018)[URL]
106. Wang TJ, "Obesity and the risk of new-onset atrial fibrillation", JAMA, 292, pp.2471~2477 (2004)
107. Lavie CJ, "Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis : effects of weight loss and exercise", J Am Coll Cardiol, 70, pp.2022~2035 (2017)
108. Sivasambu B, "Increased rates of atrial fibrillation recurrence following pulmonary vein isolation in overweight and obese patients", J Cardiovasc Electrophysiol, 29, pp.239~245 (2018)
109. Abed HS, "Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation : a randomized clinical trial", JAMA, 310, pp.2050~2060 (2013)
110. Chagnac A, "Glomerular hemodynamics in severe obesity", Am J Physiol Renal Physiol, 278, pp.F817~F822 (2000)
111. Wallace JL, "Comparison of initial warfarin response in obese patients versus non-obese patients", J Thromb Thrombolysis, 36, pp.96~101 (2013)
112. Stangier J, "Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects", Clin Pharmacokinet, 47, pp.47~59 (2008)
113. Liesenfeld KH, "Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial", J Thromb Haemost, 9, pp.2168~2175 (2011)
114. Stangier J, "The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects", Br J Clin Pharmacol, 64, pp.292~303 (2007)
115. Mueck W, "Rivaroxaban : population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention", Clin Pharmacokinet, 50, pp.675~686 (2011)
116. Kubitza D, "Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban(BAY 59-7939)in healthy subjects", J Clin Pharmacol, 47, pp.218~226 (2007)
117. Upreti VV, "Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects", Br J Clin Pharmacol, 76, pp.908~916 (2013)
118. Yin OQP, "Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation", Eur J Clin Pharmacol, 70, pp.1339~1351 (2014)
119. Martin K, "Use of the direct oral anticoagulants in obese patients : guidance from the SSC of the ISTH", J Thromb Haemost, 14, pp.1308~1313 (2016)
120. Burnett AE, "Guidance for the practical management of the direct oral anticoagulants(DOACs)in VTE treatment", J Thromb Thrombolysis, 41, pp.206~232 (2016)
121. Breuer L, "Ischemic stroke in an obese patient receiving dabigatran", N Engl J Med, 368, pp.2440~2442 (2013)
122. Safouris A, "Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient", J Neurol Sci, 346, pp.366~367 (2014)
123. Sandhu RK, "The 'obesity para dox' in atrial fibrillation : observations from the ARISTOTLE(apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation)trial", Eur Heart J, 37, pp.2869~2878 (2016)
124. Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism", N Engl J Med, 369, pp.799~808 (2013)
125. Balla SR, "Relation of risk of stroke in patients with atrial fibrillation to body mass index(from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial)", Am J Cardiol, 119, pp.1989~1996 (2017)
126. Hokusai-VTE Investigators, "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism", N Engl J Med, 369, pp.1406~1415 (2013)
127. Braekkan SK, "Obesity and risk of bleeding : the SMART study", J Thromb Haemost, 14, pp.65~72 (2016)
128. Lee CH, "Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran", Int J Cardiol, 228, pp.771~778 (2017)
129. De Caterina R, "The non-vitamin K antagonist oral anticoagulants(NOACs)and extremes of body weight-a systematic literature review", Clin Res Cardiol, 106, pp.565~572 (2017)
130. Van Eijkeren MA, "Menorrhagia : a review", Obstet Gynecol Surv, 44, pp.421~429 (1989)
131. Huq FY, "Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation", Contraception, 84, pp.128~132 (2011)
132. De Crem N, "Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists", Thromb Res, 136, pp.749~753 (2015)
133. Martinelli I, "Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use", Blood, 127, pp.1417~1425 (2016)
134. Brekelmans MP, "Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin", Thromb Haemost, 117, pp.809~815 (2017)
135. Scheres L, "Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism : a post hoc analysis of the Hokusai-VTE study", BJOG, 125, pp.1581~1589 (2018)
136. Beyer-Westendorf J, "Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy : a case series", Lancet Haematol, 3, pp.e480~e488 (2016)
137. Rolden HJ, "Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation : empirical evidence needed", BMC Cardiovasc Disord, 17, pp.260~ (2017)
138. Tobenkin A, "Direct oral anticoagulants and menorrhagia in premenopausal women : data from the food and drug administration adverse event reporting system and US drug utilization", Haemophilia, 23(Suppl 3), pp.43~ (2017)
139. Heidbüchel H, "Endurance sports is a risk factor for atrial fibrillation after ablation for atrial flutter", Int J Cardiol, 107, pp.67~72 (2006)
140. Nielsen JR, "The relationship between physical activity and risk of atrial fibrillation-a systematic review and meta-analysis", J Atr Fibrillation, 5, pp.789~ (2013)
141. Zhu WG, "Sex differences in the association between regular physical activity and incident atrial fibrillation : a meta-analysis of 13 prospective studies", Clin Cardiol, 39, pp.360~367 (2016)
142. Kwok CS, "Physical activity and incidence of atrial fibrillation : a systematic review and meta-analysis", Int J Cardiol, 177, pp.467~476 (2014)
143. Caselli S, "Prevalence and management of systemic hypertension in athletes", Am J Cardiol, 119, pp.1616~1622 (2017)
144. Kirchhof P, "2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
145. Stefanidou M, "Incidence of seizures following initial ischemic stroke in a community-based cohort : The Framingham Heart Study", Seizure, 47, pp.105~110 (2017)
146. Beghi E, "Incidence and predictors of acute symptomatic seizures after stroke", Neurology, 77, pp.1785~1793 (2011)
147. Hesdorffer DC, "Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure", Epilepsia, 50, pp.1102~1108 (2009)
148. Stöllberger C, "Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs", Epilepsy Res, 126, pp.98~101 (2016)
149. Hu YF, "Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients", Int J Cardiol, 165, pp.355~357 (2013)
150. Onaitis M, "Risk factors for atrial fibrillation after lung cancer surgery : analysis of the Society of Thoracic Surgeons general thoracic surgery database", Ann Thorac Surg, 90, pp.368~374 (2010)
151. Guglin M, "Introducing a new entity : chemotherapy-induced arrhythmia", Europace, 11, pp.1579~1586 (2009)
152. Farmakis D, "Insights into onco-cardiology : atrial fibrillation in cancer", J Am Coll Cardiol, 63, pp.945~953 (2014)
153. Horsted F, "Risk of venous thromboembolism in patients with cancer : a systematic review and meta-analysis", PLoS Med, 9, pp.e1001275~ (2012)
154. Caine GJ, "The hypercoagulable state of malignancy : pathogenesis and current debate", Neoplasia, 4, pp.465~473 (2002)
155. Lenneman CG, "Cardio-oncology : an update on cardiotoxicity of cancer-related treatment", Circ Res, 118, pp.1008~1020 (2016)
156. Raskob GE, "Edoxaban for the treatment of cancer-associated venous thromboembolism", N Engl J Med, 378, pp.615~624 (2018)
157. Young AM, "Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : results of a randomized trial(SELECT-D)", J Clin Oncol, 36, pp.2017~2023 (2018)
158. Posch F, "Treatment of venous thromboembolism in patients with cancer : a network meta-analysis comparing efficacy and safety of anticoagulants", Thromb Res, 136, pp.582~589 (2015)
159. Brunetti ND, "Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer : a meta-analysis study", Int J Cardiol, 230, pp.214~221 (2017)
160. Melloni C, "Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer : insights from the ARISTOTLE trial", Am J Med, 130, pp.1440~1448.e1441 (2017)
161. Laube ES, "Rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation and active cancer", Am J Cardiol, 120, pp.213~217 (2017)
162. Ording AG, "Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation : a Danish nationwide population-based cohort study", Cancer Med, 6, pp.1165~1172 (2017)
163. Shah S, "Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation", Blood Adv, 2, pp.200~209 (2018)
164. 김규, "Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer", Korean Circulation Journal, 48(5), pp.406~417 (2018), 대한심장학회[DOI]
165. Short NJ, "New oral anticoagulants and the cancer patient", Oncologist, 19, pp.82~93 (2014)
166. Zamorano JL, "2016ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines : the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC)", Eur Heart J, 37, pp.2768~2801 (2016)
167. Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Europace, 18, pp.1609~1678 (2016)
168. Stergiopoulos K, "Genotype-guided vs clinical dosing of warfarin and its analogues : meta-analysis of randomized clinical trials", JAMA Intern Med, 174, pp.1330~1338 (2014)
169. Kovacs MJ, "Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial", Ann Intern Med, 138, pp.714~719 (2003)
170. Garcia P, "Warfarin initiation nomograms for venous thromboembolism", Cochrane Database Syst Rev, 7, pp.D007699~ (2013)
171. Belley-Cote EP, "Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis", Thromb Haemost, 114, pp.768~777 (2015)
172. van Schie RM, "Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data", Eur Heart J, 32, pp.1909~1917 (2011)
173. Mahtani KR, "Optimal loading dose of warfarin for the initiation of oral anticoagulation", Cochrane Database Syst Rev, 12, pp.CD008685~ (2012)
174. Jones M, "Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation : a record linkage study in a large British population", Heart, 91, pp.472~477 (2005)
175. Van Spall HG, "Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries : an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy(RE-LY)trial", Circulation, 126, pp.2309~2316 (2012)
176. Wallentin L, "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)
177. Fitzmaurice DA, "Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing : a randomized, controlled trial", Arch Intern Med, 160, pp.2343~2348 (2000)
178. Wilson SJ, "Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians : a randomized controlled trial", CMAJ, 169, pp.293~298 (2003)
179. Heneghan CJ, "Self-monitoring and self-management of oral anticoagulation", Cochrane Database Syst Rev, 7, pp.CD003839~ (2016)
180. Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism", N Engl J Med, 361, pp.2342~2352 (2009)
181. EINSTEIN Investigators, "Oral rivaroxaban for symptomatic venous thromboembolism", N Engl J Med, 363, pp.2499~2510 (2010)
182. EINSTEIN?PE Investigators, "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism", N Engl J Med, 366, pp.1287~1297 (2012)
183. Agnelli G, "Apixaban for extended treatment of venous thromboembolism", N Engl J Med, 368, pp.699~708 (2013)
184. Schulman S, "Extended use of dabigatran, warfarin, or placebo in venous thromboembolism", N Engl J Med, 368, pp.709~718 (2013)
185. Weitz JI, "Rivaroxaban or aspirin for extended treatment of venous thromboembolism", N Engl J Med, 376, pp.1211~1222 (2017)
186. Huang J, "Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials", Thromb Haemost, 105, pp.245~253 (2010)
187. Eriksson BI, "Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial", Thromb Haemost, 105, pp.721~729 (2011)
188. Eriksson BI, "Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial", J Thromb Haemost, 5, pp.2178~2185 (2007)
189. Fuji T, "Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty : the STARS E-3 trial", Thromb Res, 134, pp.1198~1204 (2014)
190. Fuji T, "Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty : STARS J-V", Thromb J, 13, pp.27~ (2015)
191. Eriksson BI, "Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty", N Engl J Med, 358, pp.2765~2775 (2008)
192. Kakkar AK, "Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty : a double-blind, randomised controlled trial", Lancet, 372, pp.31~39 (2008)
193. Lassen MR, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty", N Engl J Med, 358, pp.2776~2786 (2008)
194. Turpie AG, "Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty(RECORD4) : a randomised trial", Lancet, 373, pp.1673~1680 (2009)
195. Eikelboom JW, "Rivaroxaban with or without aspirin in stable cardiovascular disease", N Engl J Med, 377, pp.1319~1330 (2017)

관련 논문AI추천